Drugs like Wegovy can be effective at treating fatty liver disease

A breakthrough discovery has shown that a well-known drug used for treating obesity and diabetes could also be beneficial in combating a serious liver condition. Semaglutide, known by brand names such as Ozempic and Wegovy, has been found to not only aid in weight loss and blood sugar regulation but also in halting or reversing metabolic dysfunction-associated steatohepatitis (MASH).

Previously known as NASH, MASH is a severe form of non-alcoholic fatty liver disease characterized by the accumulation of fat in the liver, leading to inflammation, fibrosis, and potentially cirrhosis and cancer. Often associated with obesity and type 2 diabetes, MASH poses a significant health risk.

In a recent study conducted by researchers, it was observed that a daily injection of semaglutide resulted in reduced liver fat and inflammation in 59% of patients with MASH. However, a separate study with a weekly injection regimen did not show the same benefits.

To further explore the potential of semaglutide in treating MASH, a larger trial involving 1195 patients across 37 countries was initiated. Participants were given weekly injections of semaglutide or a placebo for a period of four and a half years, alongside lifestyle counseling promoting a healthy diet and exercise.

After 72 weeks, biopsy results from the initial 800 patients revealed promising outcomes. Those receiving semaglutide showed significant reductions in liver fat and inflammation, with improvements in fibrosis compared to the placebo group. Weight loss was also noted in the treated group, further contributing to the positive effects of the drug.

While the exact mechanisms behind semaglutide’s impact on MASH are still being investigated, researchers believe that the drug may target the disease-causing processes, potentially through immune cell modulation to reduce inflammation.